DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Grail - 4 Illumina - 2 PWNHealth - 2 Bill Gates - 2 Jeff - 2 Simon Stevens - 2 Galleri - 1 That's - 1
Top related locs:
U.S California Regatul Unit Illumina San Diego , California American Bengaluru
Top related orgs:
CNN - 2 Universitatea Cambridge - 2 The Securities - 1 Exchange Commission - 1 SEC - 1 Union - 1 The European Commission - 1 Illumina - 1

Search resuls for: "Galleri"


11 mentions found


☆ This $1,000 Test Finds Signs of Cancer in Your Blood
  + stars: | 2023-10-25 | by ( Alex Janin | ) www.wsj.com   time to read: 1 min
Doctors, researchers and patient advocates are excited about a new blood test that promises to detect cancer early. They disagree about whether you should actually use it yet. The $949 Galleri liquid biopsy can screen for more than 50 types of cancers. It works by looking for a shared cancer signal in DNA shed by tumors in the bloodstream. More than 130,000 of the prescription-only tests have been sold since Galleri became available in June 2021, according to the test maker Grail, a unit of the gene-sequencing company Illumina .
Persons: Galleri
☆ SEC investigating Illumina over acquisition of cancer test developer Grail
  + stars: | 2023-08-11 | by ( Annika Kim Constantino | ) www.cnbc.com   time to read: +2 min
The Securities and Exchange Commission is investigating Illumina over its controversial $7.1 billion acquisition of cancer test developer Grail, the DNA sequencing company said in a securities filing late Thursday. Last month, the SEC informed Illumina about the probe and requested documents and communications related to the deal. The company's market value has fallen to roughly $28 billion from around $75 billion the month the deal closed. Illumina's Grail deal has also faced heavy scrutiny from antitrust regulators in the U.S. and European Union. The European Commission, the EU's executive body, fined Illumina a record $476 million last month for closing the acquisition without first securing regulatory approval.
Persons: Illumina, That's, Carl Icahn Organizations: The Securities, Exchange Commission, SEC, Union, The European Commission, Illumina, U.S . Federal Trade Commission Locations: Illumina, San Diego , California, U.S
☆ Hundreds Were Mistakenly Told They Might Have Cancer, Test Company Says
  + stars: | 2023-06-04 | by ( Amanda Holpuch | ) www.nytimes.com   time to read: 1 min
A company that developed a blood test that detects dozens of types of cancer has acknowledged that about 400 of its customers were mistakenly told last month that they might have the disease. The company, Grail, said in an emailed statement on Sunday that a vendor it works with had sent hundreds of letters with incorrect test results because of a “software configuration issue” that has since been resolved. The letters went to customers who had recently purchased Grail’s Galleri test, which uses a blood draw to detect a cancer signal shared by 50 types of cancer and is available only by prescription. The problem was not caused by inaccurate test results, Grail said. More than half of the people who received the letter in error had not yet had their blood drawn for the test, the company said.
Persons: Grail
☆ Around 400 patients were wrongly informed they might have cancer, biotech company says
  + stars: | 2023-06-03 | by ( Isobel Van Hagen | ) www.businessinsider.com   time to read: +2 min
A biotech company said 400 people had been mistakenly informed they might have cancer. Grail Inc said the error resulted from a software issue, which has been resolved. The incident was part of a trial of an early-detection blood test called Galleri. Grail Inc, an American biotechnology company, developed an early-detection blood test called Galleri, created to identify more than 50 types of cancer before symptoms appear, per Reuters. The company, owned by gene sequencing company Illumina, said it promptly contacted patients after the incident.
Persons: —, Grail, PWNHealth, MassMutual Organizations: Inc, Service, Financial Times, British Locations: American
☆ Grail says about 400 patients incorrectly informed they may have cancer
  + stars: | 2023-06-02 | by ( ) www.reuters.com   time to read: +1 min
Companies Grail Inc FollowIllumina Inc FollowJune 2 (Reuters) - Cancer test maker Grail Inc (GRAL.O) said on Friday that its telemedicine vendor erroneously sent letters to about 400 patients suggesting they may have developed cancer. Grail's flagship cancer detection blood test Galleri is designed to detect more than 50 types of cancer before symptoms appear. Grail said it had reached out to the patients immediately after the issue, adding that no patient health information has been disclosed or breached due to this. The software issue being faced by PWNHealth has now been resolved, it said. Illumina is currently appealing regulatory orders in the U.S. and EU, which are asking the gene sequencing company to divest Grail after it jumped regulators to close its acquisition of the cancer test maker.
Persons: Grail, PWNHealth, Illumina, Mariam Sunny, Shilpi Majumdar Organizations: Illumina Inc, Thomson Locations: U.S, Bengaluru
☆ New Blood Tests Offer Possible Early Detection of Cancer and Alzheimer’s
  + stars: | 2023-04-18 | by ( Laura Landro | ) www.wsj.com   time to read: 1 min
Galleri test samples being received and approved for processing in Grail Inc.’s Durham, N.C., lab. Photo: Grail Inc.New blood tests are taking on a growing role in early detection of such diseases as cancer and Alzheimer’s, among the most devastating health risks that emerge in aging. Using a single blood sample, one test released last year can detect early signals for more than 50 types of cancer, including some such as pancreatic cancer for which no routine preventive screening assays have existed up to this point. Other blood tests are proving accurate in detecting amyloid plaques—the proteins that clump together in the brains of Alzheimer’s patients, leading to eventual loss of memory and thinking skills—even before cognitive declines have been experienced.
☆ FTC orders Illumina to divest $7.1 billion acquisition of cancer test developer Grail
  + stars: | 2023-04-03 | by ( Annika Kim Constantino | ) www.cnbc.com   time to read: +3 min
The Federal Trade Commission on Monday ordered Illumina to divest its controversial acquisition of cancer test developer Grail, saying the deal would stifle competition and innovation. The decision reverses an administrative judge's September ruling, which dismissed the FTC's initial challenge to the $7.1 billion deal. Illumina said in a statement that it intends to appeal the FTC's decision in federal court and will seek an expedited decision. "The acquisition of GRAIL potentially gives Illumina incentives to favor GRAIL over its rivals by providing GRAIL preferential access or preferential terms for acquiring NGS inputs," the FTC said. Illumina also "stands to earn substantially more profit on the sale of GRAIL tests than it does by supporting rival test developers," the commission added.
☆ Cancer researchers question antitrust arguments against Illumina-Grail deal
  + stars: | 2022-12-16 | by ( Deena Beasley Julie Steenhuysen | Deena Beasley | Julie Steenhuysen | ) www.reuters.com   time to read: +6 min
"The jury is still out," on which technology will dominate, said Dr. Sadik Esener, director of the Cancer Early Detection Advanced Research Center at the OHSU Knight Cancer Institute in Portland, Oregon. He added it could take as long as 20 years to show that an early cancer detection test saved lives. If proven to work, early cancer detection tests could help doctors identify cancer risk in patients long before symptoms or other indicators develop. DIFFERENT APPROACHESSeveral of the leading contenders take vastly different approaches to cancer detection and it is not yet clear which methods will prove most useful or when. Some are working on blood tests to detect different markers of early cancer, including proteins.
☆ Illumina's Grail expands use of cancer detection test with life insurer deal
  + stars: | 2022-09-20 | by ( Deena Beasley | ) www.reuters.com   time to read: +3 min
REUTERS/Mike Blake/File PhotoSept 20 (Reuters) - Cancer detection test maker Grail, acquired by Illumina Inc (ILMN.O) last year despite ongoing antitrust challenges, on Tuesday said it would expand use of its flagship Galleri test through a new agreement with life insurer John Hancock, a division of Manulife Financial (MFC.TO). The test, designed to detect more than 50 types of cancer before symptoms appear, looks at the DNA in a patient's blood to determine whether any come from cancer cells. Data have shown that, across the 50 cancer types, including early-stage to late-stage, the Galleri test correctly identified the presence of cancer in 51.5% of cases. read moreJohn Hancock said it is the first life insurance carrier to offer, under its wellness program, policyholder access to Grail's early cancer detection test. The U.S. Federal Trade Commission filed a lawsuit in March 2021 to stop the acquisition on the basis that it would slow innovation for cancer detection tests.
☆ Cercetătorii străini anunță că vor lansa un test rapid ce ar putea detecta 50 de tipuri de cancer în stadiu incipient
  + stars: | 2020-11-28 | by ( Praporșcic Maria | ) www.zdg.md   time to read: +2 min
Testul de sânge „Galleri” a fost dezvoltat de compania Grail din California și va fi folosit pentru prima oară pentru 165 de mii de pacienți, a anunțat NHS într-un comunicat de presă. Reprezentanții NHS mai spun că testele de sânge ar putea fi extrem de utile în identificarea tipurilor de cancer care sunt dificil de diagnosticat și tratat timpuriu. Peste o mie de oameni sunt diagnosticați cu cancer zilnic în Regatul Unit”, a declarat Simon Stevens, directorul executiv al NHS. Nu toți experții oncologi sunt de părere însă că NHS ar trebui să efectueze acest program-pilot. Un profesor de la Universitatea Cambridge a declarat că are dubii cu privire la eficiența acestui test, în contextul datelor limitate care au fost publicate.
Persons: Bill Gates, Jeff, Simon Stevens Organizations: CNN, Universitatea Cambridge Locations: California, Regatul Unit
☆ Descoperirea care ar revoluționa medicina. Un nou test rapid ar putea detecta 50 de tipuri de cancer
  + stars: | 2020-11-28 | by ( Publika.Md - Aici Sunt Știrile | ) www.publika.md   time to read: +2 min
Testul de sânge „Galleri” a fost dezvoltat de o companie din California, Grail, și va fi folosit pentru prima oară pentru 165.000 de pacienți, a anunțat NHS într-un comunicat de presă, vineri. Grail, a cărei activitate se concentrează pe soluții pentru detectarea timpurie a cancerului, este susținută de miliardari americani precum Bill Gates sau Jeff Bezos, scrie digi24.ro. Peste 1000 de persoane sunt diagnosticate cu cancer zilnic în Regatul Unit”, a declarat Simon Stevens, directorul executiv al NHS. Ceilalți 25.000 vor fi persoane cu posibile simptome de cancer pentru care testele vor fi folosite pentru a detecta mai rapid boala. Paul Pharoah, profesor la Universitatea Cambridge spune că are dubii cu privire la eficiența acestui test, în contextul datelor limitate care au fost publicate.
Persons: Grail, Bill Gates, Jeff, Simon Stevens, Paul Pharoah Organizations: CNN, Universitatea Cambridge Locations: California, Regatul Unit
0 next >>
Total: 11